| abstract |
Disclosed is the use of 1-hydroxy-2- (imidazol-1-yl) ethane-1,1-diphosphonic acid (zoledronic acid), its pharmaceutically acceptable salts and hydrates in the preparation of medicaments for the treatment of abnormally elevated bone turnover states, wherein the acid 1 -hydroxy-2- (imidazol-1-yl) ethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, is administered intermittently and the period between administrations is at least about six months. |